Selin Bolca

Company: MRM Health

Job title: Dir Operations and Development

Seminars:

MH002, an Optimized Consortia Therapeutic for Inflammatory Bowel Diseases, Combines Clinical Efficacy with an Excellent Safety Profile in a Phase 2a Study in Ulcerative Colitis 12:00 pm

MH002, a 6-strain consortia therapeutic designed, optimized and manufactured through MRM Health’s CORAL® technology, is the most advanced live biotherapeutic in clinical development for Ulcerative Colitis and Pouchitis Receive first-time insight in the integrated data from a placebo-controlled randomized phase 2a study of MH002 in Ulcerative Colitis patients, combining clinical efficacy and safety profileRead more

day: Day 2 Track A AM

Panel Discussion: Microbiome, Dosing & Toxicity – Regulatory Lessons Learned & Questions Still Remaining 2:45 pm

Exploring engraftment and microbiome-therapeutic efficacy Outlining challenges in determining dosing Navigating toxicity concernsRead more

day: Day 1 Track A PM